Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival

Ege, Çiğdem Berna; Akbulut, Metin; Zekioğlu, Osman; Özdemir, Necmettin

doi:10.1007/s00404-010-1766-9

Cited by 12 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no significant difference was found in the heparanase expression in patients with cancer according to prognosis factors. This was also the case for the study by Ege et al, 29 who used the same antibody used in our investigation and were not able to identify differences in the HPSE1 expression comparing the prognosis factors in 64 endometrium carcinomas, except for deep myometrial invasion (P = 0.022). The hypothesis that there might be a difference between the expression of heparanases in glandular and stromal tissue of the endometrium and in different types of nonneoplastic and neoplastic tissues was partially confirmed in this study: the finding of a high frequency of HPSE2 expression in the stromal tissue of women with secretory endometrium is worth highlighting because it might indicate a possible protector role of HPSE2 when secreted in the stroma.…”

Section: Discussionsupporting

confidence: 56%

Immunohistochemical Expression of Heparanases 1 and 2 in Benign Tissue and in Invasive Neoplasia of the Endometrium: A Case-Control Study

Filho¹,

Focchi²,

Theodoro

et al. 2015

Int J Gynecol Cancer

View full text Add to dashboard Cite

Heparanase 1 is more intensely expressed in the glandular tissue of high-grade compared with type I carcinomas. Heparanase 2 is more intensely expressed in the glandular tissue of cancer than in nonneoplastic endometrium, whereas the HPSE2 expression in the stromal tissue is higher in the nonneoplastic controls compared with the group of patients with cancer mainly in the secretory endometrium. This suggests that HPSE2 might be stimulated by progesterone, with a possible antineoplastic role, antagonist to HPSE1, to be further investigated.

show abstract

Section: Discussionsupporting

confidence: 56%

Immunohistochemical Expression of Heparanases 1 and 2 in Benign Tissue and in Invasive Neoplasia of the Endometrium: A Case-Control Study

Filho¹,

Focchi²,

Theodoro

et al. 2015

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Contradictory to the data by Van den Brule et al [58], Brustmann et al [60] were able to show an increase in galectin-3 in EMCAR samples compared with normal endometrium samples. However, Ege et al [61] reported decreased galectin-3 expression in EMCAR samples compared with normal endometrium. We currently found no increased galectin-1 or galectin-3 expression in tissue lysates of EMCAR or US compared with normal/benign controls.…”

Section: Discussionmentioning

confidence: 99%

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Vanderstraeten

Luyten

Verbist

et al. 2014

Cancer Immunol Immunother

109

101

View full text Add to dashboard Cite

The major hurdle for cancer vaccines to be effective is posed by tumor immune evasion. Several common immune mechanisms and mediators are exploited by tumors to avoid immune destruction. In an attempt to shed more light on the immunosuppressive environment in uterine tumors, we analyzed the presence of PD-L1, PD-L2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin-1, galectin-3, arginase-1 activity and myeloid-derived suppressor cell (MDSC) infiltration. IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemistry. PD-L2 was mostly expressed at low levels in these tumors. We found high IDO expression in 21 % of endometrial carcinoma samples and in 14 % of uterine sarcoma samples. For PD-L1 and B7-H4, we found high expression in 92 and 90 % of endometrial cancers, respectively, and in 100 and 92 % of the sarcomas. Galectin-1 and 3 were analyzed in tissue lysates by ELISA, but we did not find an increase in both molecules in tumor lysates compared with benign tissues. We detected expression of galectin-3 by fibroblasts, immune cells and tumor cells in single-cell tumor suspensions. In addition, we noted a highly significant increase in arginase-1 activity in endometrial carcinomas compared with normal endometria, which was not the case for uterine sarcomas. Finally, we could demonstrate MDSC infiltration in fresh tumor suspensions from uterine tumors. These results indicate that the PD-1/PD-L1 interaction and B7-H4 could be possible targets for immune intervention in uterine cancer patients as well as mediation of MDSC function. These observations are another step toward the implementation of inhibitors of immunosuppression in the treatment of uterine cancer patients.Electronic supplementary materialThe online version of this article (doi:10.1007/s00262-014-1537-8) contains supplementary material, which is available to authorized users.

show abstract

“…Galectin-1 is differentially expressed in several tumors in the female reproductive tract. An increased expression of galectin-1 protein is found in endometrial [ 102 , 103 ], breast [ 104 ], ovarian [ 105 ], and cervical [ 106 ] cancers. The intensity of galectin-1 expression also increases according to the pathologic grade of cervical [ 106 ] or breast [ 104 ] cancer and correlates with the depth of invasion of the cervical cancer and in lymph node metastases [ 107 ].…”

Section: Galectins In Tumors Of the Female Reproductive Tractmentioning

confidence: 99%

Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia

Than¹,

Romero

Balogh³

et al. 2015

J Pathol Transl Med

View full text Add to dashboard Cite

Galectins are an evolutionarily ancient and widely expressed family of lectins that have unique glycan-binding characteristics. They are pleiotropic regulators of key biological processes, such as cell growth, proliferation, differentiation, apoptosis, signal transduction, and pre-mRNA splicing, as well as homo- and heterotypic cell-cell and cell-extracellular matrix interactions. Galectins are also pivotal in immune responses since they regulate host-pathogen interactions, innate and adaptive immune responses, acute and chronic inflammation, and immune tolerance. Some galectins are also central to the regulation of angiogenesis, cell migration and invasion. Expression and functional data provide convincing evidence that, due to these functions, galectins play key roles in shared and unique pathways of normal embryonic and placental development as well as oncodevelopmental processes in tumorigenesis. Therefore, galectins may sometimes act as double-edged swords since they have beneficial but also harmful effects for the organism. Recent advances facilitate the use of galectins as biomarkers in obstetrical syndromes and in various malignancies, and their therapeutic applications are also under investigation. This review provides a general overview of galectins and a focused review of this lectin subfamily in the context of inflammation, infection and tumors of the female reproductive tract as well as in normal pregnancies and those complicated by the great obstetrical syndromes.

show abstract

Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival

Cited by 12 publications

References 45 publications

Immunohistochemical Expression of Heparanases 1 and 2 in Benign Tissue and in Invasive Neoplasia of the Endometrium: A Case-Control Study

Immunohistochemical Expression of Heparanases 1 and 2 in Benign Tissue and in Invasive Neoplasia of the Endometrium: A Case-Control Study

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia

Contact Info

Product

Resources

About